Impaired glucose tolerance: Do pharmacological therapies correct the underlying metabolic disturbance?

British Journal of Diabetes and Vascular Disease

Volumn 3, Issue SUPPL. 1, 2003, Pages

  DeFronzo, Ralph A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Beta cell dysfunction; Impaired glucose tolerance; Insulin resistance; Metformin; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE; INCRETIN DERIVATIVE; INSULIN; METFORMIN; PIOGLITAZONE; PRAVASTATIN; RAMIPRIL; RECOMBINANT HORMONE; ROSIGLITAZONE; SULFONYLUREA; TETRAHYDROLIPSTATIN; THIAZOLIDINE DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BEHAVIOR MODIFICATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC DIET; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG POTENCY; EXERCISE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET CELL FUNCTION; PATHOGENESIS; REVIEW; WEIGHT REDUCTION;

EID: 0038574723     PISSN: 14746514     EISSN: None     Source Type: Journal    
DOI: 10.1177/1474651403003001s0601     Document Type: Review

References (143)

1. DeFronzo RA. Lilly Lecture. The triumvariate: beta cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-87.
2. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 1997;15: 177-269.
3. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism 1989;38:387-95.
4. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, DeFronzo RA. Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-13.
5. Gastaldelli A, Baldi S, Pettiti M et al. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. Diabetes 2000;49:1367-73.
6. 13C nuclear magnetic resonance study. J Clin Invest 1992;90:1323-7.
7. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22-9.
8. Bonadonna RC, Del Prato S, Bonora E et al. Roles of glucose transport and glucose phosphorylation in muscle insulin resistance of NIDDM. Diabetes 1996,45:915-25.
9. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in non-insulin-dependent (type II) diabetes mellitus. J Clin Invest 1985;76:149-55.
10. 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990,322:223-8.
11. Reaven GM, Hollenbeck CB, Chen YDI. Relationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose tolerance. Diabetologia, 1989;32:52-5.
12. Gulli G, Ferrannini E, Stern M, Haffner S, DeFronzo RA. The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents. Diabetes 1992;41:1575-86.
13. Cusi K, Maezono K, Osman A et al. Insulin resistance differentially affects the PI 3-kinase and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:311-20.
14. Pratipanawatr W, Pratipanawatr T, Cusi K et al. Skeletal muscle insulin resistance in normoglycaemic subjects with a strong family history of type 2 diabetes is associated with decreased insulin-stimulated IRS-1 tyrosine phosphorylation. Diabetes 2001;50:2572-8.
15. Shepherd PR, Kahn B. Mechanisms of disease: glucose transporters and insulin action - implications for insulin resistance and diabetes mellitus. N Engl J Med 1999;341:248-57.
16. Mandarino LJ, Printz RL, Cusi KA et al. Regulation of hexokinase II and glycogen synthase mRNA, protein, and activity in human muscle. Am J Physiol 1995,269:E701-E708.
17. Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777-83.
18. Kahn SE. Clinical Review 135. The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047-58.
19. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1989;1:1356-9.
20. Brunzell JD, Robertson RP, Lerner RL et al. Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 1976;42:222-9.
21. Luzi L, DeFronzo RA. Effect of loss of first phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol 1989;20:E241-E246.
22. Yalow RS, Benson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157-75.
23. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Internal Med 2000;133:73-4.
24. Eriksson KF, Lingarde F. Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. Diabetologia 1991;34: 891-8.
25. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Quing IGT and diabetes study. Diabetes Care 1997;20:537-44.
26. Tuomilehto J, Lindstrom J, Eriksson JG et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
27. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
28. McGarry JD: Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18.
29. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997;46:3-10.
30. Reaven GM: The fourth musketeer - from Alexandre Dumas to Claude Bernard. Diabetologia 1995;38:3-13.
31. Groop LC, Bonadonna RC, Del Prato S, Ratheiser K, Zyck K, DeFronzo RA. Effect of insulin on oxidative and non-oxidative pathways of glucose and FFA metabolism in NIDDM. Evidence for multiple sites of insulin resistance. J Clin Invest 1989;84:205-13.
32. Reaven GM. Banting Lecture: role of insulin resistance in human disease. Diabetes 1988;37:595-607.
33. Kashyap S, Belfort R, Pratipanawatr T et al. Effect of a chronic elevation in plasma free fatty acids on insulin secretion and action in nondiabetic offspring with a strong family history of T2DM. Diabetes 2002; 51(suppl 2):A12.
34. McGarry JD. Banting Lecture 2001. Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18.
35. Ferrannini E, Barrett EJ, Bevilacqua S, DeFronzo RA. Effect of fatty acids on glucose production and utilization in man. J Clin Invest 1983;72: 1737-47.
36. Thiebaud D, DeFronzo RA, Jacot E et al. Effect of long chain triglyceride infusion on glucose metabolism in man. Metabolism 1982;21:1128-36.
37. Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and free fatty acid metabolism in type 2 diabetic patients. Diabetologia 2001;44:2210-19.
38. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in NIDDM. J Clin Endo Metab 1996;81:4059-67.
39. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998;6:89-131.
40. Johnson AB, Webster JM, Sum CF et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993; 42:1217-22.
41. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:550-4.
42. DeFronzo RA, Goodman AM. The Multicenter Metformin Study Group. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1995;333:541-9.
43. Widen E, Erikson J, Groop L. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycaemic first degree relatives of patients with NIDDM. Diabetes 1992;41:354-8.
44. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin: synergism with insulin. Biochem Pharmacol 1988;37:4353-8.
45. Rossetti L, DeFronzo RA, Gherzi R et al. Insulin receptor tyrosine kinase activity and in vivo insulin action in diabetic rats. Effect of metformin treatment. Metabolism 1990;39:425-35.
46. Stith BJ, Goalstone ML, Espinoza R, Mossel C, Roberts D, Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinol 1996;137:2990-9.
47. Stith B, Woronoff K, Wiernsperger N. Stimulation of the intracellular portion of the human insulin receptor by the antidiabetic drug metformin. Biochem Pharmacol 1998;55:533-6.
48. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990;13:696-704.
49. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H. Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 1994;37:826-32.
50. Detaille D, Wiernsperger N, Devos P. Potentiating effect of metformin on insulin-induced glucose uptake and glycogen metabolism with Xenopus oocytes. Diabetologia 1998;41:2-8.
51. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
52. Mithieux G, Guignot L, Bordet J-C, Wiernsperger N. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 2002;51:139-43.
53. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS34). Lancet 1998;352:854-65.
54. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
55. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.
56. Meyer MM, Levin K, Grimmsmann T et al. Troglitazone treatment increases protein kinase B phosphorylation in skeletal muscle of normoglycaemic subjects at risk for the development of type 2 diabetes. Diabetes 2002;51:2691-7.
57. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycaemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-19.
58. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-91.
59. Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone improves downstream insulin-receptor signaling in type 2 diabetic patients. Diabetes 2003 (in press).
60. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51:797-802.
61. Wolffenbuttel BH, Sels JP, Huijberts MS. Rosiglitazone. Expert Opin Pharmacother 2001;2:467-78.
62. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther 2001;23:1792-823.
63. Mudaliar S, Henry RR. New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med 2001;52:239-57.
64. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes mellitus. Diabetes Care 2002;25:517-23.
65. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, Buckingham RE. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001;50: 1021-9.
66. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Nat Acad Sci USA 1999;96: 11513-18.
67. Kim YB, Ciaraldi TF, Kong A et al. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p 110 β protein levels in skeletal muscle of type 2 diabetic subjects. Diabetes 2002;51:443-8.
68. Buchanan TA, Xiang AH, Peters RK. Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-803.
69. Antonucci T, Whitcomb R, McClain R, Lockwood D. Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone. Diabetes Care 1997;20:188-93.
70. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997; 100:530-7.
71. Gastaldelli A, Miyazaki Y, Pettiti M et al. Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab 2002;87: 5098-103.
72. Bjorntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991;14:1132-43.
73. Miyazaki Y, Hardies LJ, Wajcberg E et al. Effect of pioglitazone on liver fat content, abdominal fat distribution, and insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes 2002;51(suppl 2):A69.
74. Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes mellitus. Diabetes 2003 (in press).
75. Miyazaki Y, Hardies JL, Wajcberg E et al. Effect of pioglitazone on liver fat content, abdominal fat distribution, and insulin sensitivity in type 2 diabetic patients. Diabetes 2002;51(suppl 2):A69.
76. Ryysy L, Hakkinen AM, Goto T et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 2000;49:749-58.
77. 1H NMR spectroscopy study. Diabetologia 1999;42:113-16.
78. Stein DT, Szczepanik L, Dobbins R, McGarry JD. Increasing intramyocellular triglyceride stores are associated with impaired glucose tolerance and NIDDM. Diabetes 1999;48(suppl 1):A287.
79. Goodpaster BH, Thaete FL, Simoneau JA, Kelley DE. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 1997;46:1579-85.
80. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999;277:E1130-E1141.
81. Greco AV, Mingrone G, Giancaterini A et al. Insulin resistance in morbid obesity: reversal with intramyocellular fat depletion. Diabetes 2002; 51:144-51.
82. 13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 1999;48:1600-06.
83. Khan MA, St. Peter JV, Xue JL. A prospective, randomised comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002;25:708-11.
84. de Souza CJ, Eckhardt M, Gagen K et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001;50:1863-71.
85. Kelley IE, Walsh K, Han TS, Lean MEJ. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 1999;22:288-93.
86. Kawai T, Takei I, Oguma Y et al. Effects of troglitazone on fat distribution in the treatment of male type 2 diabetes. Metabolism 1999;48: 1102-07.
87. Pan DA, Lillioja S, Kriketos AD et al. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997;46:983-8.
88. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance. Diabetes 2000;49:677-83.
89. Itani SI, Ruderman NB, Schmieder F, Boden G. Lipid-induced insulin resistance in human muscle is associated with changes in diacylglycerol, protein kinase C, and IΚB-α. Diabetes 2002;51:2005-11.
90. Ellis BA, Poynten A, Lowy AJ et al. Long-chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat and human muscle. Am J Physiol 2000;279:E554-E560.
91. De Fea K, Roth RA. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry 1997;36:12939-47.
92. Ravichandran LV, Esposito DL, Chen J, Quon MJ. PKC-zeta phosphorylates IRS-1 and impairs its ability to activate P-3-kinase in response to insulin. J Biol Chem 2001;276:3543-9.
93. Faergeman NJ, Knudsen J. Role of long-chain fatty acyl-CoA esters in the regulation of metabolism and in cell signaling. Biochem J 1997;323:1-12.
94. Kruszynska YT, Worrall DS, Ofrecio J, Frias JP, Macaraeg G, Olefsky JM. Fatty acid-induced insulin resistance: decreased muscle P13K activation but unchanged Akt phosphorylation. J Clin Endocrinol Metab 2002;87: 226-34.
95. Thompson AL, Cooney GJ. Acyl-CoA inhibition of hexokinase in rat and human skeletal muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 2000;49:1761-4.
96. Tippett PS, Neet KE. An allosteric model for the inhibition of glucokinase by long chain acyl coenzyme A. J Biol Chem 1982;257:14846-52.
97. 12 skeletal muscle cells pretreated with palmitate. J Biol Chem 1999;274:24202-10.
98. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1996;45:273-83.
99. Shimabukuro M, Zhou YT, Levi M, Unger RH. Fatty acid induced beta cell apoptosis. Proc Natl Acad Sci 1998;95:2498-502.
100. McGarry JD: Banting Lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002;51:7-18.
101. Unger RH. How obesity causes diabetes in Zucker Diabetic Fatty rats. Trends Endocrinol Metab 1997;7:276-82.
102. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin. J Clin Invest 1987;79:1510-15.
103. Kahn B, Shulman GI, DeFronzo RA, Cushman S, Rossetti L. Normalizalion of blood glucose in diabetic rats with phlorizin treatment reverses insulin resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991;87: 561-70.
104. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037-44.
105. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care-Reviews 1990;13:610-30.
106. Massillon D, Barzailai N, Hawkins M, Prus-Wetheimer D, Rossetti L. Induction of hepatic glucose-6-phosphatase gene expression by lipid infusion. Diabetes 1997;46:153-7.
107. Leahy JL, Cooper HE, Weir GC. Impaired insulin secretion associated with near normoglycemia. Diabetes 1987;36:459-64.
108. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359: 2072-7.
109. Sartor G, Schersten B, Carlstrom S, Melander A, Norden A, Persson G. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-9.
110. DeFronzo RA, Sherwin RS, Hendler R, Felig P. Insulin binding to monocytes and insulin action in human obesity, starvation, and refeeding. J Clin Invest 1978;62:204-13.
111. Henry RR, Wallace P, Olefsky JM. Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes 1986;35:990-8.
112. Kelley DE. Effects of weight loss on glucose homeostasis in NIDDM. Diabetes Reviews 1995;3:366-77.
113. Sjostrom L, Torgeson JS, Boldrin M. XENDOS (XENical in the prevention of Diabetes in Obese Subjects): a landmark study. 9th International Congress on Obesity, Sau Paulo, Brazil, August 26, 2002.
114. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
115. Yusef S, Gerstein H, Hoogwerf B et al., for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001;286:1882-5.
116. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
117. Hansson L, Lindholmn L, Niskanen L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. Lancet 1999; 353:611-16.
118. Shiuchi T, Cui T, Wu L et al. ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. Hypertension 2002;40:329-34.
119. Folli F, Kahn C, Hansen H, Bouchie J, Feener E. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: a potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997;100:2158-69.
120. Hsueh W. Treatment of type 2 diabetic nephropathy by blockade of the rennin-agiotensin system: a comparison of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. Cur Opin Pharm 2002;2:182-8.
121. Holst J, Orskov C. Incretin hormones - an update. Scand F Clin Lab Invest 2001;234:75-85.
122. Kieffer T, Habener J. The glucagons-like peptides. Endocr Rev 1999;20: 876-913.
123. Holst JJ, Gromada J, Nauck MA. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 1997;40:984-6.
124. Drucker DJ. Glucagon-like peptides. Diabetes 1998;47:159-69.
125. Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza R. Effect of glucagon-like peptide 1 (7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes 2000;49:611-17.
126. Vaag AA, Holst JJ, Volund A, Beck-Nielsen HB. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM) - evidence for decreased glucagons-like peptide 1 secretion during oral glucose ingestion in NIDDM twins. Eur J Endocrinol 1996; 135:425-32.
127. Fineman MS, Bicsak T, Shen L et al. AC2993 (synthetic exendin-4) added to existing metformin (Met) and/or sulfonylurea (SFU treatment improved glycaemic control in patients with type 2 diabetes (DM2) during 28 days of treatment. Diabetes 2002;51(suppl 2):A85.
128. Stamler R, Stamler J, Lindberg HA et al. Asymptomatic hyperglycemia and coronary heart disease in middle-aged men in two employed populations in Chicago. J Chronic Diseases 1979;32:805-15.
129. Yarnell JW, Pickering JE, Elwood PC et al. Does non-diabetic hyperglycemia predict future IHD? Evidence from the Caerphilly and Speedwell studies. J Clin Epidemiol 1994;47:383-8.
130. Balkau B, Shipley M, Jarrett RJ et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. Diabetes Care 1998;21:360-7.
131. Butler MU, Ostrander LD Jr, Carman WJ, Lamphlear DE. Mortality from coronary heart disease in the Tecumseh Study: long-term effect of diabetes mellitus, glucose tolerance and other risk factors. Am J Epidemiol 1985;121:541-7.
132. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
133. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ASCVD. Diabetes Care-Reviews 1991;14:173-94.
134. Isomaa B, Almgren F, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24: 683-9.
135. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1988;83:2773-6.
136. Zavaroni I, Bonini L, Gasparini P et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus hypertension, and coronary heart disease: the Barilla factory revisited. Metabolism 1999;48:989-94.
137. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: The Atherosclerosis Risk in Communities Study. Diabetes 2002;51:3069-76.
138. Plutzsky J. Peroxisome proliferators-activated receptors in vascular biology and atherosclerosis: emerging insights for evolving paradigms. Current Atherosclerosis Reports 2000;2:327-35.
139. Hsueh WA, Law RE. Insulin signaling in the arterial wall. Am J Cardiol 1999;84:21J-24J.
140. Law RE, Meehan WP, Xi X-P et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-905.
141. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998;83:1818-20.
142. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-6.
143. Takagi T, Akasaka T, Yamamuro A et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:1529-35.